NCT00413075 - Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma | Biotech Hunter

Enrollment

121

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

August 31, 2011

Study Completion Date

August 31, 2011

Conditions

Solid TumorLymphoma

Interventions

DRUG

oral belinostat

oral belinostat dosed once or twice daily at continuous and discontinuous dosing schedules.

Trial Locations (6)

New York University Cancer Institute, New York

Yale New Haven Hospital, New Haven

Columbia University - Herbert Irving Cancer Center, New York

M.D. Anderson Cancer Center, Houston

Research Facility, Copenhagen

Research Facility, London